{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ianevski A"],"funding":["Norwegian Cancer Society","Austrian Science Fund FWF","Helsinki Institute of Life Science (HiLIFE)","Research Council of Finland (AKA)","Signe ja Ane Gyllenbergin Säätiö (Signe and Ane Gyllenberg Foundation)","Sigrid Juselius Foundation","Comprehensive Cancer Center Forschungsförderung der Initiative Krebsforschung","European Union's Horizon 2020 Research and Innovation Programme","Cancer Foundation of Finland"],"pagination":["295-309"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12809113"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["86(2)"],"pubmed_abstract":["T-cell leukemias and lymphomas (TCL) form a heterogeneous group of rare and often aggressive malignancies. Because of the rarity and heterogeneity of TCL subtypes, clinical trials are challenging to conduct, making pharmacogenomic studies in cell line panels critical for the discovery of targeted therapeutics. The scarcity of data repositories with integrated multiomics and drug screening data hinders the preclinical evaluation of drug vulnerabilities and the identification of molecular markers predictive of responses to monotherapies and combinations. To address this gap, we conducted comprehensive pharmacogenomic profiling on a panel of 38 TCL cell lines, representing major clinical TCL subtypes to capture the molecular and phenotypic diversity. The TCL-38 multiomics data resource includ"],"journal":["Cancer research"],"pubmed_title":["Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery."],"pmcid":["PMC12809113"],"funding_grant_id":["SFB-F06109","216104","340141","Fellow grants","273810","ERA PerMed","EP PerMed","345803","ImmuneT-ME","367855","344698","JAKSTAT-TARGET"],"pubmed_authors":["Dias D","Julia E","Kankainen M","Pirker C","Timonen S","Braun T","Nader K","Poloske D","Kadambat Nair S","Cichonska A","Haibe-Kains B","Bachy E","Wagner C","Ianevski P","Moriggl R","Aittokallio T","Jungherz D","Nguyen J","Nakano M","Spirk K","Ianevski A","Pemovska T","Mustjoki S","Berger W","Herling M","Neubauer HA","Sorger H"],"additional_accession":[]},"is_claimable":false,"name":"Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery.","description":"T-cell leukemias and lymphomas (TCL) form a heterogeneous group of rare and often aggressive malignancies. Because of the rarity and heterogeneity of TCL subtypes, clinical trials are challenging to conduct, making pharmacogenomic studies in cell line panels critical for the discovery of targeted therapeutics. The scarcity of data repositories with integrated multiomics and drug screening data hinders the preclinical evaluation of drug vulnerabilities and the identification of molecular markers predictive of responses to monotherapies and combinations. To address this gap, we conducted comprehensive pharmacogenomic profiling on a panel of 38 TCL cell lines, representing major clinical TCL subtypes to capture the molecular and phenotypic diversity. The TCL-38 multiomics data resource includ","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-06T15:37:51.612Z","creation":"2026-06-02T03:08:46.009Z"},"accession":"S-EPMC12809113","cross_references":{"pubmed":["41166698"],"doi":["10.1158/0008-5472.CAN-25-0881"]}}